Reason: MRNA's round-trip from its parabolic high kept going (RSI 54.8 to 45.9, -9.5% 7D) rather than stabilizing; VRTX held flat; AMGN stays the steadiest large-cap accumulate name for a fourth read running, per the biotech-scan; TMO cooled slightly but remains the other name with an intact thesis flag.

Tape Read

The MRNA round-trip flagged last read hasn't found a floor — RSI fell further to 45.9 (was 54.8), on a fresh -9.45% weekly decline, now -27.78% off its 52-week high. VRTX, the other name that round-tripped from an RSI-80s extreme two reads ago, has essentially gone flat this cycle: RSI 53.4 (was 53.1), +0.05% 7D, -9.0% off its high — no further slippage. AMGN remains the cleanest structure in the group: RSI 57.5 (was 58.6), +0.8% 7D, golden cross, and the biotech-scan itself calls it the "steadiest large-cap in the sector." TMO cooled modestly (RSI 64.7→62.3, +1.03% 7D) but the scan still flags it as one of only five names in the whole watchlist carrying an "intact" thesis. Source: 2026-07-17-biotech-scan + summaries/biotech.json.

• MRNA — PASS (still declining): RSI 45.9 (down from 54.8), -9.45% 7D, -27.78% off 52wk high — the round-trip from its parabolic run hasn't stabilized; still falling, not basing.
• VRTX — WATCH: RSI 53.4 (roughly flat from 53.1), +0.05% 7D, -9.0% off high — the earlier de-risking has paused rather than continued.
• AMGN — PROMOTE: RSI 57.5, strong-up, golden cross, +0.8% 7D — cleanest large-cap structure in the sector for a fourth straight read.
• TMO — PROMOTE/WATCH: RSI 62.3 (down from 64.7), death-crossed but "up" trend, thesis flagged intact, +14.61% 30D — steady climber, unchanged story.

Lead pick: AMGN — still the least-drama name in the group and the one the scan itself calls the sector's steadiest large-cap. MRNA is the one to watch: its post-parabolic decline is still running, not resolving.

Sources

• Tape data (price/RSI/SMA/returns): full-scan pre-computed summaries as of the 2026-07-17 close — *.